The therapeutic effect of Beta-D mannuronic acid in breast cancer patients

Phase 1

• Conditions: Condition 1: Breast cancer. Condition 2: Breast cancer. Condition 3: Breast cancer. Condition 4: Breast cancer. Condition 5: Breast cancer. Condition 6: Breast cancer. Condition 7: Breast cancer. Condition 8: Breast cancer.; Malignant neoplasm: upper-inner quadrant of breast; Malignant neoplasm: upper-outer quadrant of breast; Malignant neoplasm: axillary tail of breast; Malignant neoplasm: overlapping lesion of breast; Malignant neoplasm: breast, unspecified; Malignant neoplasm: lower-inner quadrant of breast; Malignant neoplasm: nipple and areola; Malignant neoplasm: lower-outer quadrant of breast

• Registration Number: IRCT2017012213739N7
• Lead Sponsor: Vice-Chancellor for Research, Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 36

Inclusion Criteria

Inclusion Criteria: 30-60 years old patients, Diagnosed with breast cancer according to American College of oncology Diagnostic Criteria after the initial visit by a specialist in cancer surgery and parameters CEA, CA15.3, CBC and sonography, Each patient must sign written informed consent.

Exclusion Criteria

History of fever and Infectious diseases, Positive pregnancy test or Lactation, Other collagen- vascular and auto immune diseases, Patients have enrolled another clinical trial study within last 4 weeks, Other concomitant diseases (Hepatic, renal, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease).

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Feel the mass and tenacity in breast. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Examination by specialist.

Secondary Outcome Measures

Name	Time	Method
Tumor size. Timepoint: At baseline and after 12 weeks of treatment. Method of measurement: Sonography.